Loading clinical trials...
Loading clinical trials...
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Gl...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Zealand Pharma
NCT05561647 · Short Bowel Syndrome (SBS)
NCT06973304 · Short Bowel Syndrome
NCT06427642 · Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia, and more
NCT06938542 · Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, and more
NCT05635747 · Short Bowel Syndrome, Malabsorption
Washington University Center for Advanced Medicine
St Louis, Missouri
Lied Transplant Center at Nebraska Medical Center
Omaha, Nebraska
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions